165 related articles for article (PubMed ID: 15372069)
1. Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector.
Smyth JW; Fleeton MN; Sheahan BJ; Atkins GJ
Gene Ther; 2005 Jan; 12(2):147-59. PubMed ID: 15372069
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles.
Murphy AM; Morris-Downes MM; Sheahan BJ; Atkins GJ
Gene Ther; 2000 Sep; 7(17):1477-82. PubMed ID: 11001367
[TBL] [Abstract][Full Text] [Related]
3. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice.
Lyons JA; Sheahan BJ; Galbraith SE; Mehra R; Atkins GJ; Fleeton MN
Gene Ther; 2007 Mar; 14(6):503-13. PubMed ID: 17167497
[TBL] [Abstract][Full Text] [Related]
5. Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12.
Chikkanna-Gowda CP; Sheahan BJ; Fleeton MN; Atkins GJ
Gene Ther; 2005 Aug; 12(16):1253-63. PubMed ID: 15944731
[TBL] [Abstract][Full Text] [Related]
6. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.
Daemen T; Riezebos-Brilman A; Regts J; Dontje B; van der Zee A; Wilschut J
Antivir Ther; 2004 Oct; 9(5):733-42. PubMed ID: 15535411
[TBL] [Abstract][Full Text] [Related]
7. Recombinant Semliki Forest virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell response.
Colmenero P; Berglund P; Kambayashi T; Biberfeld P; Liljeström P; Jondal M
Gene Ther; 2001 Sep; 8(17):1307-14. PubMed ID: 11571567
[TBL] [Abstract][Full Text] [Related]
8. Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus.
Yamanaka R; Zullo SA; Ramsey J; Onodera M; Tanaka R; Blaese M; Xanthopoulos KG
Cancer Gene Ther; 2001 Oct; 8(10):796-802. PubMed ID: 11687903
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibitory effect of triple anti-tumor gene transfer using Semliki Forest virus vector in glioblastoma cells.
Lee JS; Lee JH; Poo H; Kim MS; Lee SH; Sung MH; Kim CJ
Int J Oncol; 2006 Mar; 28(3):649-54. PubMed ID: 16465369
[TBL] [Abstract][Full Text] [Related]
10. Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector.
Guan M; Rodriguez-Madoz JR; Alzuguren P; Gomar C; Kramer MG; Kochanek S; Prieto J; Smerdou C; Qian C
Cancer Res; 2006 Feb; 66(3):1620-9. PubMed ID: 16452221
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with recombinant Semliki Forest virus particles expressing translation initiation factor 3 of Brucella abortus induces protective immunity in BALB/c mice.
Cabrera A; Sáez D; Céspedes S; Andrews E; Oñate A
Immunobiology; 2009; 214(6):467-74. PubMed ID: 19150742
[TBL] [Abstract][Full Text] [Related]
12. Activation of peritoneal cells upon in vivo transfection with a recombinant alphavirus expressing GM-CSF.
Klimp AH; van der Vaart E; Lansink PO; Withoff S; de Vries EG; Scherphof GL; Wilschut J; Daemen T
Gene Ther; 2001 Feb; 8(4):300-7. PubMed ID: 11313804
[TBL] [Abstract][Full Text] [Related]
13. Vesicular stomatitis virus glycoprotein: a transducing coat for SFV-based RNA vectors.
Dorange F; Piver E; Bru T; Collin C; Roingeard P; Pagès JC
J Gene Med; 2004 Sep; 6(9):1014-22. PubMed ID: 15352074
[TBL] [Abstract][Full Text] [Related]
14. A Semliki forest virus vector engineered to express IFNα induces efficient elimination of established tumors.
Quetglas JI; Fioravanti J; Ardaiz N; Medina-Echeverz J; Baraibar I; Prieto J; Smerdou C; Berraondo P
Gene Ther; 2012 Mar; 19(3):271-8. PubMed ID: 21734727
[TBL] [Abstract][Full Text] [Related]
15. Murine polyomavirus virus-like particles (VLPs) as vectors for gene and immune therapy and vaccines against viral infections and cancer.
Tegerstedt K; Franzén AV; Andreasson K; Joneberg J; Heidari S; Ramqvist T; Dalianis T
Anticancer Res; 2005; 25(4):2601-8. PubMed ID: 16080500
[TBL] [Abstract][Full Text] [Related]
16. A vaccination strategy consisting of Semliki-Forest-virus (SFV) DNA prime and fowlpox-virus boost significantly protects mice from a recombinant (HIV-1) vaccinia-virus infection.
Quintana-Vázquez D; Vázquez-Blomquist DM; Galbán Rodríguez E; Herrera Buch AM; Duarte Cano CA
Biotechnol Appl Biochem; 2005 Feb; 41(Pt 1):59-66. PubMed ID: 15099194
[TBL] [Abstract][Full Text] [Related]
17. Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition.
de Mare A; Lambeck AJ; Regts J; van Dam GM; Nijman HW; Snippe H; Wilschut J; Daemen T
Gene Ther; 2008 Mar; 15(6):393-403. PubMed ID: 18004406
[TBL] [Abstract][Full Text] [Related]
18. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice.
Chahlavi A; Rabkin S; Todo T; Sundaresan P; Martuza R
Gene Ther; 1999 Oct; 6(10):1751-8. PubMed ID: 10516725
[TBL] [Abstract][Full Text] [Related]
19. Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas.
Rodriguez-Madoz JR; Prieto J; Smerdou C
Mol Ther; 2005 Jul; 12(1):153-63. PubMed ID: 15963931
[TBL] [Abstract][Full Text] [Related]
20. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene.
Colmenero P; Liljeström P; Jondal M
Gene Ther; 1999 Oct; 6(10):1728-33. PubMed ID: 10516722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
